Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

Courtney D. DiNardo(The University of Texas MD Anderson Cancer Center), Keith W. Pratz(Sidney Kimmel Comprehensive Cancer Center), Anthony Letai(Dana-Farber Cancer Institute), Brian A. Jonas(UC Davis Comprehensive Cancer Center), Andrew H. Wei(Monash University), Michael J. Thirman(University of Chicago Medical Center), Martha Arellano(Emory University), Mark G. Frattini(Columbia University Irving Medical Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Relja Popovic(AbbVie (United States)), Brenda Chyla(AbbVie (United States)), Tu Xu(AbbVie (United States)), Martin Dunbar(AbbVie (United States)), Suresh Agarwal(AbbVie (United States)), Rod Humerickhouse(AbbVie (United States)), Mack Mabry(AbbVie (United States)), Jalaja Potluri(AbbVie (United States)), Marina Konopleva(The University of Texas MD Anderson Cancer Center), Daniel A. Pollyea(University of Colorado Denver)
The Lancet Oncology
January 12, 2018
Cited by 708

Abstract


Related Papers

No related papers found

Powered by citation graph analysis